Organize your questions and next steps, then save your worksheet.
Summary and next steps
Tell both the diabetes and eye teams about existing retinopathy and the planned semaglutide treatment. Obtain an individual follow-up and contact plan.
- Share prior retinal diagnoses and treatments.
- Ask whether baseline eye information is adequate.
- Write down the next visit and urgent contact instructions.
Editorial maintenance: October 24, 2026. Summary layout, related links and technical metadata updated. This is not a full clinical review.
If you have diabetic retinopathy and are starting semaglutide, ask your diabetes and eye teams to coordinate monitoring. There is no universal blog-based recheck schedule.
Share the existing eye diagnosis
Tell the prescriber about retinopathy, macular edema, previous laser or injections, and any current symptoms. Ask the eye clinic whether your existing examination is an adequate baseline or whether an assessment is needed sooner.
Bring the planned medicine changes and available glucose records. Do not delay necessary diabetes treatment solely to complete a blog checklist; the clinicians should decide how to coordinate care.
Make the follow-up plan individual
The retinal stage, current edema, prior treatment and expected change in diabetes control all matter. Ask the eye team to state the next visit date and whether dose changes or new symptoms should prompt contact.
Do not assume that every person needs the same visit at the same number of weeks, or that an annual screening appointment is enough for established retinal disease. Keep already prescribed retinal treatment appointments.
Separate different safety questions
Diabetic retinopathy and NAION are different conditions. EMA has identified NAION as a very rare adverse effect of semaglutide. That does not mean that all blur during treatment is NAION or that every GLP-1 medicine has the same evidence.
Sudden vision loss or rapidly worsening eyesight needs assessment without delay. If NAION is confirmed, EMA advises stopping semaglutide; the treating clinicians should coordinate the medication decision and the diabetes plan.
Leave with a written contact plan
Ask: What is my current retinal diagnosis? When is my next examination? Which symptoms mean I should call immediately? Who handles a concern outside office hours?
Record the exact product, dose and recent changes. Do not use a symptom score, a cover-one-eye test or improvement after blinking to clear a new visual symptom, and do not change medication independently because of this article.
Sources and next step
Bring your questions to your care team. Prepare an appointment question list or report a correction.
Editorial revision: October 22, 2026. Replaced checklist-based monitoring and fixed timing with an individualized eye-and-diabetes follow-up plan. Prepared by a non-clinician; source checking does not replace individual medical or insurance advice. Editorial policy.
PUT THIS GUIDE TO WORK · INTERACTIVE WORKSHEET
Prepare coordinated eye-monitoring questions
Use this worksheet alongside the article: Starting Semaglutide With Diabetic Retinopathy: Monitoring. Use the fields provided to organize your notes and next actions, then save your worksheet.
Your entries stay in this page and are cleared when you reload. No account is needed. Saved files are downloaded only to your device.
This card organizes a discussion or task. It does not provide diagnosis, treatment, medication timing, driving clearance, or professional approval. Copy clinical instructions exactly and ask the professional about uncertainty.
How to use your result
Save the worksheet before leaving this page. Recheck any quote, date, or instruction with the relevant provider, pharmacist, manufacturer, or official organization. A completed checklist means you recorded the steps, not that an outcome is guaranteed.
Worksheet added October 20, 2026. Read the article above for context and its stated review scope.